{
    "nct_id": "NCT05921253",
    "official_title": "Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)",
    "inclusion_criteria": "1. Patients (>50 years) who have received anthracycline-based therapy (a cumulative dose of ≥ 200 mg/m2 Doxorubicin or bioequivalent dose of other anthracyclines) for breast cancer or lymphoma within the last 15-30 days and have >= 1 of following additional criteria:\n\n* previous chest radiation,\n* type 2 diabetes mellitus,\n* hypertension,\n* current smoking,\n* obesity (BMI ≥ 30),\n* previous myocardial infarction or\n* established atherosclerotic heart disease.\nHealthy volunteers allowed\nMust have minimum age of 50 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "1. atrial paced rhythm,\n2. history of seizure currently on treatment,\n3. history of vasovagal syncope,\n4. end stage liver or kidney disease.",
    "miscellaneous_criteria": ""
}